Claims for Patent: 6,949,527

Summary for Patent: 6,949,527

Title:	6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
Abstract:	Disclosed is a 6-mercapto-cyclodextrin derivative having a general formula (I, ) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6) alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o -phenylene-CH.sub.2).sub.p --; o and p are independently 0-4; X is COOH, CONHR.sub.3, NHCOR.sub.2, SO.sub.2 OH, PO(OH).sub.2, O(CH.sub.2 --CH.sub.2 --O).sub.q --H, OH or tetrazol-5-yl: R.sub.2 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block.
Inventor(s):	Zhang; Mingqiang (Montreal, CA), Palin; Ronald (Near Kilsyth, GB), Bennett; David Jonathan (Edinburgh, GB)
Assignee:	Akzo Nobel N.V. (Arnhem, NL)
Application Number:	10/603,355
Patent Claims:	1. A kit for providing neuromuscular block and its reversal comprising (a) an aminosteroidal neuromuscular blocking agent and (b) a reversal agent selected from the group consisting of 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(3-carboxypropyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(2-carboxypropyl)thio-.gamma.-cyclodextrin; and 6-per-deoxy-6-per-(2-sulfoethyl)thio-.gamma.-cyclodextrin; or a pharmaceutically acceptable salt thereof. 2. A kit according to claim 1 wherein the aminosteroidal neuromuscular blocking agent is selected from the group consisting of rocuronium bromide, vecuronium bromide, pancuronium bromide, and rapacuronium bromide, or another pharmaceutically acceptable salt thereof. 3. A kit according to claim 2, wherein the neuromuscular blocking agent is rocuronium bromide and the reversal agent is 6-per-deoxy-6per-(2-carboxyethyl)thio-.gamma.-cyclodextrin sodium salt. 4. A method of treatment of a patient with a neuromuscular blocking agent comprising the steps or (a) inducing the neuromuscular block by administration of an effective amount of an aminosteroidal blocking agent selected from the group consisting of rocuronium bromide, vecuronium bromide, pancuronium bromide and rapacuronium bromide, or another pharmaceutically acceptable salt thereof, and (b) reversing the drug-induced neuromuscular block by administration of an effective amount of at least one reversal agent selected from the group consisting of 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(3-carboxypropyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(2-carboxypropyl)thio-.gamma.-cyclodextrin; and 6-per-deoxy-6-per-(2-sulfoethyl)thio-.gamma.-cyclodextrin; or a pharmaceutically acceptable salt thereof. 5. The method of treatment according to claim 4, wherein the neuro-muscular blocking agent is rocuronium bromide and the reversal agent is 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin sodium salt.